Table 2.
In vitro stability of CIY and IPY to simulated gizzard and intestine conditions as assessed by ELISA.
Treatments | Time (h) |
|||
---|---|---|---|---|
0.5 | 1 | 2 | 3 | |
Gizzard | ||||
IPY | 0.57 ± 0.06a | 0.51 ± 0.13a | 0.47 ± 0.10b | 0.45 ± 0.07a |
CIY | 0.46 ± 0.10a | 1.35 ± 0.7a | 1.8 ± 0.36a | 0.43 ± 0.05a |
P-value | 0.87 | 0.047 | 0.0002 | 0.67 |
Intestine | ||||
IPY | 0.42 ± 0.09a | 0.41 ± 0.07a | 0.41 ± 0.11b | 0.44 ± 0.11b |
CIY | 0.45 ± 0.06a | 0.50 ± 0.12a | 1.36 ± 0.26a | 1.13 ± 0.11a |
P-value | 0.83 | 0.86 | 0.0001 | 0.0001 |
a-bMeans within a column lacking a common superscripts differ (P < 0.01).
Abbreviations: CIY, capsulated immune yolk; IPY, immune powdered yolk; SGDJ, simulate avian gizzard digestive juice; SIDJ, simulate intestinal digestive juice.
Anti-SI IgY activity remaining over 3 h incubation in SGDJ and SIDJ was measured by ELISA.
Values represent the mean ± SD, (n = 6).